Author | Tanya Siddiqi, MD

Articles

Outlook for 2017: Acute Leukemias, MDS, and CLL

December 26, 2016

This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of acute leukemias, myelodysplastic syndromes, and chronic lymphocytic leukemia.

Outlook for 2017: Myeloma, Lymphoma, and MPNs

December 23, 2016

ByAmrita Y. Krishnan, MD

Robert Chen, MD

Tanya Siddiqi, MD

David Snyder, MD

This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloproliferative neoplasms.

Novel Biologic Agents for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia-Part 2: Adoptive Cellular Immunotherapy, Small-Molecule Inhibitors, and Immunomodulation

April 15, 2015

ByTanya Siddiqi, MD

Steven T. Rosen, MD

In this review we discuss adoptive cellular immunotherapies, small-molecule inhibitors, and immunomodulatory agents. We also mention other novel therapies on the horizon.

Novel Biologic Agents for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia-Part 1: Monoclonal Antibodies

March 15, 2015

ByTanya Siddiqi, MD

Steven T. Rosen, MD

Here we review monoclonal antibodies that have received FDA approval for the treatment of NHL and CLL in the last 5 years, as well as promising agents in development.